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Lysyl hydroxylases catalyze hydroxylation of collagen lysines, and sustain essential roles in
extracellular matrix (ECM) maturation and remodeling. Malfunctions in these enzymes cause
severe connective tissue disorders. Human lysyl hydroxylase 3 (LH3/PLOD3) bears multiple
enzymatic activities, as it catalyzes collagen lysine hydroxylation and also their subsequent
glycosylation. Our understanding of LH3 functions is currently hampered by lack of molecular
structure information. Here, we present high resolution crystal structures of full-length
human LH3 in complex with cofactors and donor substrates. The elongated homodimeric LH3
architecture shows two distinct catalytic sites at the N- and C-terminal boundaries of each
monomer, separated by an accessory domain. The glycosyltransferase domain displays
distinguishing features compared to other known glycosyltransferases. Known disease-
related mutations map in close proximity to the catalytic sites. Collectively, our results
provide a structural framework characterizing the multiple functions of LH3, and the mole-
cular mechanisms of collagen-related diseases involving human lysyl hydroxylases.
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Collagen biosynthesis requires multiple post-translationalmodiﬁcations essential for the generation of mature,triple-helical molecules1. Modiﬁcation of collagen lysines
enables subsequent glycosylation and formation of extracellular
cross-links, leading to ﬁbrillary or meshwork superstructures2.
Enzymes belonging to the family of collagen lysyl hydroxylases
(LH or PLOD) catalyze lysine hydroxylation of collagens using
Fe2+, 2-oxoglutarate (2-OG), ascorbate and molecular oxygen3,4.
In humans, PLOD genes encode for three LH enzyme isoforms
sharing >60% amino acid sequence identity: LH1, LH2a/b, and
LH3, respectively5. Mutations in PLOD genes that reduce or
abolish LH activity are associated with severe connective tissue
diseases including Ehlers-Danlos6 and Bruck syndromes7,8. In
mouse models, LH3 knock-outs are embrionically lethal9,10.
Mutations in the PLOD3 gene also result in impaired collagen
glycosylation, secretion, and basement membrane formation,
yielding phenotypes resembling osteogenesis imperfecta11. Con-
versely, PLOD overexpression and upregulated enzymatic activity
have been linked to ﬁbrosis12, and recently also to hypoxia-
induced metastatic spreading of solid tumors with poor prog-
nosis13–15.
LH3 is considered the evolutionary ancestor of the LH family:
this isoform is the only one capable of further processing of
hydroxylysines through glycosylation, whereas other isoforms
might have lost such capability during evolution16. LH3 is
therefore a multifunctional enzyme capable of converting col-
lagen lysines into 1,2-glucosylgalactosyl-5-hydroxylysines
through three consecutive reactions: hydroxylation of collagen
lysines (LH activity), N-linked conjugation of galactose to
hydroxylysines (GT activity), and conjugation of glucose to
galactosyl-5-hydroxylysines (GGT activity)17,18. Biochemical data
suggest that these different enzymatic activities are localized in
distinct compartments of the enzyme19, but despite the extensive
evidence available, the current knowledge of LH enzymes is far
from exhaustive. These enzymes are known to act together with
prolyl hydroxylases, respectively introducing hydroxylations of
lysine and proline residues on procollagens in the endoplasmic
reticulum (ER), prior to the formation of triple-helical assem-
blies20. In line with this, LH enzymes are found as ER-resident
proteins albeit they do not possess speciﬁc ER-retention
sequences21,22. Reports suggest that ER retention could be
mediated via interaction with distinct ER-resident proteins: LH1
is described to be part of a macromolecular complex with SC65,
P3H3 and CYPB23; while LH2 forms a complex with HSP47,
FKBP65 and BiP24,25; LH3 was found colocalizing with collagen
galactosyltransferases GLT25D1/226. Multiple reports identify
LH3 also in the extracellular space and suggest dedicated traf-
ﬁcking mechanisms for its secretion27–30. Abnormalities in LH3
post-Golgi trafﬁcking are associated with devastating develop-
mental diseases with phenotypes characterized by immature
collagen accumulation and lack of its secretion, very similar to
those observed in case of enzyme malfunctions caused by knock-
down or inactivation9–11,30,31. Very recently, LH2 secretion has
been reported associated with hypoxia-induced PLOD2 over-
expression in metastatic tumor microenvironments13,15. Extra-
cellular LHs were reported to be active, suggesting implications
for ECM stability and remodeling27. These data indicate that
although lysine modiﬁcations are known to occur in the ER prior
to collagen triple helical formation, secreted variants of LH3 and
LH2 can modify collagens in different compartments and, pos-
sibly, in different folding states32.
The accumulated knowledge about the precise molecular roles
and mechanisms associated with LH enzymes has suffered from
the lack of molecular structure models fundamental to shed light
on the complexity and the diversity of this important enzyme
family. Here, we present the crystal structures of multifunctional
full-length human LH3 in complex with various cofactors and
donor substrates. The structures reveal a multidomain archi-
tecture characterized by two independent catalytic sites devoted
to the different enzymatic activities and provide a molecular
understanding that has implications for various disease-related
mutations found in LH enzymes. Altogether, our results offer new
insights into the complex mechanisms of collagen biosynthesis
and homeostasis, and provide structural templates for the
development of targeted therapies for LH-related diseases and
cancer.
Results
LH3 has three domains encompassing multiple catalytic sites.
We have generated human stable cell lines for large-scale pro-
duction of full length, glycosylated human LH3, and established
methods for its puriﬁcation and evaluation of its LH and GT
enzymatic activities (Supplementary Fig. 1). ICP-MS analyses
indicated that all enzyme preparations contained Fe2+ with a
1:1 stoichiometry (see Methods). We observed signiﬁcant
uncoupling (up to 25%) of donor substrate activation, with
substrate-independent generation of the succinate or UDP reac-
tion products, respectively. Nevertheless, we could detect sig-
niﬁcantly increased enzymatic activity in the presence of synthetic
peptides (Supplementary Fig. 1C) or gelatin (Supplementary
Fig. 1D) as acceptor substrates. We could conﬁrm such reactivity
by detection of concentration-dependent binding (Supplementary
Fig. 2A) and appearance of post-translationally modiﬁed lysine
residues on synthetic peptides upon LH3 treatment (Supple-
mentary Fig. 2B). In our peptide binding measurements, all
surface plasmon resonance (SPR) proﬁles were characterized by
very fast association and dissociation events and very weak
(millimolar) binding afﬁnities (Supplementary Fig. 2A).
Crystal structures of LH3 were determined in complex with
various substrates and cofactors at resolutions ranging between
2.1 and 3.0 Å (Supplementary Table 1). Diffraction data were
systematically affected by strong anisotropy (Supplementary
Fig. 3), thus structure determination required anisotropy
correction followed by a combination of experimental phasing
with heavy atom and highly redundant native single wavelength
anomalous dispersion (SAD), eventually yielding electron density
maps of superb quality (Supplementary ﬁg. 4A, B). Residues
Asn63 and Asn548 showed extended electron densities protrud-
ing from their side chains (Supplementary ﬁg. 4C), indicating the
expected N-linked glycosylations. The LH3 monomer encom-
passes three domains aligned along one direction (Fig. 1a). The
ﬁrst two N-terminal domains show Rossmann-fold architectures
reminiscent of glycosyltransferases33,34, whereas the C-terminal
domain is characterized by a double-stranded β-helix (DSBH)
fold, highly conserved among the 2-OG, Fe2+-dependent
dioxygenases35,36. Overall, the three-dimensional structure of
the LH3 full-length enzyme provides a molecular blueprint to
elucidate previous suggestions on the enzyme architecture based
on biochemical data: GT and GGT activities localize at the N-
terminus of the enzyme, whereas the LH activity is segregated at
the LH3 C-terminus37,38.
LH3 forms elongated tail-to-tail dimers. Although the asym-
metric units of our LH3 crystal structures contain a single LH3
monomer, previous biochemical studies20,38 and our size exclu-
sion chromatography coupled to small-angle X-ray scattering
(SEC-SAXS) analyses consistently showed 200 kDa dimers in
solution (Supplementary Fig. 1A). The crystal packing indeed
suggests two homodimeric arrangements with physiologically
plausible assemblies (Supplementary Fig. 5). A ﬁrst, elongated,
tail-to-tail quaternary structure shares nearly identical dimer
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interface with that observed recently in a C-terminal fragment of
a viral LH homolog (L230-LH)39. This interface interconnects the
C-terminal domains of LH3 and exposes individual glycosyl-
transferase domains at the two sides of the dimer (Supplementary
Fig. 5B). A second, more compact antiparallel conformation is
characterized by contacts between the glycosyltransferase
domains and exposes individual lysyl hydroxylase domains at the
two sides of the dimer (Supplementary Fig. 5C). Both interfaces
are characterized by a large buried surface area and numerous
hydrogen bonds and hydrophobic interactions. Previous bio-
chemical characterizations based on C-terminal LH3 deletions
indicated residues Lys541-Glu547 as essential for dimerization38.
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Fig. 1Molecular architecture of human LH3. a Cartoon representation of the LH3 enzyme, showing its organization with three domains aligned from the N-
to the C- terminus. Based on results of functional assays, the ﬁrst two glycosyltransferase domains have been named GT (catalytic glycosyltransferase,
blue) and AC (accessory, orange), respectively. The C-terminal domain hosts the Fe2+ and 2-OG cofactors necessary for lysyl hydroxylase activity, and
therefore has been named LH (green). Metal ions are shown as spheres, cofactors and glycans as sticks. b Introduction of additional glycosylation sites
identiﬁes the LH3 dimer interface in solution. Glycosylated mutants R714N and T672N induce disruption of the dimeric assembly, as observed in analytical
size exclusion chromatography experiments. Control glycosylated mutant W148N-L150T, located at a crystal contact interface, is a dimer as wild-type LH3.
c Overview of the LH3 dimer as observed in the crystal structures. The quaternary arrangement highlights an elongated tail-to-tail dimer extending for over
20 nm in one direction, connected through strong electrostatic and hydrophobic interactions near the LH catalytic site. Fe2+ and 2-OG in the neighboring
catalytic site are shown with spheres and sticks, respectively. For clarity, one LH3 monomer is colored as in a, whereas the other is shown in white. d The
molecular interface connecting two C-terminal LH domains in the LH3 crystal structure is characterized by strong hydrophobic interactions involving
Leu715 of one monomer (green) and various aromatic residues shaping a cavity on the opposite monomer (white). This hydrophobic contact is surrounded
by electrostatic interactions. For clarity, only the amino acids of one monomer are labeled. e Details of the LH3 dimer interface. Shown is the electrostatic
potential computed using APBS70 colored from −10 kbTec−1 (red) to +10 kbTec−1 (blue)
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In our structures, both observed dimeric assemblies fully support
this statement, as this region is located in a linking platform
connecting the central glycosyltransferase domain with the C-
terminal domain (Fig. 1a). Initial attempts using SAXS and
computational methods to discriminate between crystallographic
contacts and stable dimers in solution (Supplementary Fig. 5–6)
were not conclusive. A recent report suggested that in both
homologous viral L230-LH domain and in human LH2, repla-
cement of the fully conserved, surface-exposed C-terminal residue
Leu715 (LH3 numbering, located in the middle of the “elongated”
dimer interface found in the LH3 crystal structure) with a charged
Asp could disrupt the enzyme’s dimeric assembly and generate
inactive, monomeric species in solution39. We took advantage of
this information and introduced the corresponding L715D
mutation in LH3; we also opted for generating a second mutant,
bearing a positive Arg side chain replacing Leu715. Surprisingly,
the L715D mutant was comparable to wild-type LH3 in activity
assays and in analytical size exclusion chromatography experi-
ments, while we observed slightly increased retention volumes
and abolished LH activity for the L715R mutant (Supplementary
Fig. 7). Similarly, removal of Fe2+ using chelating agents and
acidiﬁcation, successfully exploited to destabilize both viral LH
and human LH2 dimer interfaces39 did not seem to affect
LH3 stability (Supplementary Fig. 7C). We therefore decided to
introduce more pronounced steric hindrance at the observed
crystallographic dimer interfaces, through mutations carrying
additional glycosylation sites. Mutants T672N and R714N, both
adding a glycosylation near the C-terminal dimer interface as
veriﬁed by SDS-PAGE and enzymatic deglycosylation experi-
ments (Supplementary Fig. 7A, B, Supplementary Fig. 17), shifted
the size exclusion retention volumes towards monomeric species
(Fig. 1b) and abolished LH activity (Supplementary Fig. 7D). On
the contrary, the LH3 mutant W148N-L150T, introducing an
additional glycosylation at the “compact” N-terminal interface
did not affect the dimeric quaternary structure of LH3 nor the LH
enzymatic activity (Fig. 1b, Supplementary Fig. 7D). We therefore
concluded that the physiological LH3 dimeric assembly corre-
sponds to the elongated, tail-to-tail arrangement shown in Fig. 1c.
This interface is characterized by two-fold symmetric interactions
involving a rather limited set of aminoacid side chains engaged in
electrostatic contacts, plus a deep hydrophobic cavity shaped by
Phe673, Phe639, Tyr642 and Thr672 hosting the side chain of
Leu715 from the opposite monomer (Fig. 1d, e).
Structural insights into LH3 glycosyltransferase activity. The
N-terminal LH3 glycosyltransferase domain partially shares ter-
tiary structure topology with divalent metal ion-dependent class-
A glycosyltransferase folds (GT-A)33, but with distinguishing
structural features as expected given the very low sequence
identity conservation, lower than 12%. Indeed, although numer-
ous three-dimensional structures of GT-A glycosyltransferases are
available in the protein data bank, superpositions with even the
closest structural homolog yielded root mean square deviations (r.
m.s.d.) higher than 3 Å (Supplementary Fig. 8A). Notably, this
LH3 domain lacks a highly conserved α-β hairpin at its N-
terminus near residue Gly70, and includes other structural ele-
ments surprisingly well conserved at the primary sequence level
within the LH enzyme family (Supplementary Fig. 9), but distinct
from other glycosyltransferases. In particular, the conformations
of four loops differ from GT-A structures and shape the
substrate-binding face of the N-terminal domain of LH3 (Sup-
plementary Fig. 8A). Among these, a very ﬂexible surface loop
comprising residues Gly72 to Gly87 is not visible in the electron
density of ligand-free LH3 structures. This loop contains several
residues highly conserved among LH isoforms (Supplementary
Fig. 9), which are not found in other glycosyltransferases. A cavity
characterized by aspartate residues 112 and 115 and
His253 shapes the metal ion binding site. Co-crystallizations with
Mn2+ resulted in appearance of strong electron density prox-
imate to these residues for the metal ion and two coordinating
water molecules, without observable conformational changes
compared to ligand-free LH3 (Supplementary Fig. 10A). Co-
crystallizations with Mn2+ and donor substrates UDP-galactose
or UDP-glucose yielded additional clear electron densities for
UDP, but not for the glycan moieties (Fig. 2a). We observed weak
electron density near the UDP pyrophosphate group partially
compatible with glycan donor substrates, but we refrain from
modeling anything inside this weak density, likely representative
of multiple conformations simultaneously trapped in the sub-
strate binding cavity (Supplementary Fig. 10B). We could not
detect signiﬁcant differences when comparing co-crystal struc-
tures obtained using UDP-Gal or UDP-Glc donor substrates.
Nonetheless, binding of these donor substrates induced dramatic
conformational changes in the enzyme’s catalytic site, with full
stabilization of the ﬂexible Gly72-Gly87 loop in a “closed” con-
formation (Fig. 2b). The UDP pyrophosphate group is stabilized
by interactions with Mn2+ and hydrogen bonding with Lys259
and backbone nitrogen of Gly256; both residues are positioned in
a uniquely shaped α-helix located at the C-terminus of the
domain. The hydroxyl groups of the ribose form a network of
hydrogen bonds with backbone atoms of Ser113 and Tyr114. The
uracil moiety is sandwiched through π-π stacking interactions
between Trp75 and Tyr114, and is stabilized by hydrogen
bonding with Thr46 (Fig. 2a, b, Supplementary Fig. 10). Of note,
these two residues highlight an unprecedented arrangement of
UDP binding residues in glycosyltransferases: Trp75 belongs to
the distinctive LH3 ﬂexible loop covering residues Gly72-Gly87,
that becomes fully stabilized upon substrate binding (Fig. 2b);
Tyr114 is part of a non-canonical DxxD motif (Supplementary
ﬁg. 9), where Asp112, and Asp115 are responsible for Mn2+
coordination. Structurally related glycosyltransferases also often
bear tyrosine residues stacking with the UDP moiety, but these
residues are located far in sequence from the canonical DxD
motif40,41 responsible for metal ion coordination. Site-directed
mutagenesis on Trp75 or Tyr114 into alanine residues yielded
folded, but almost completely inactive LH3 variants (Fig. 2c,
Supplementary ﬁg. 11). Binding data using SPR on synthetic
collagen peptides showed very limited differences between wild-
type and mutant LH3 (Supplementary Fig. 11D). Together, these
results highlight the distinguishing roles of Trp75 and Tyr114 in
donor substrate binding and stabilization.
Two tryptophan residues Trp145 and Trp148 proximate to the
UDP-binding cavity consistently change their side chain
conformations in structures with bound donor substrates
(Fig. 2b). In UDP-glycan-bound structures, residue Trp145
adopts a conformation that can easily accommodate the sugar
moiety during catalysis (Fig. 2b). In the absence of donor
substrates this residue partially obstructs the cavity, thus acting as
a gating residue to host the UDP-glycan (Fig. 2b). Trp148
localizes on the LH3 surface, in a region distant from the
glycosyltransferase catalytic site located at the interface between
two crystallographically related LH3 molecules. Interestingly,
both Trp145 and Trp148 residues are located in one of the loops
that are not conserved neither in glycosyltransferases, nor in
other LH enzymes (Supplementary Fig. 9): this region may
therefore have a role in recognition and binding of donor and/or
acceptor substrates, highlighting the unusual mechanisms of LH3
GT/GGT activity. Of note, mutagenesis studies aimed at
characterizing LH3 GT/GGT activities showed that residues in
this loop are indeed critical for LH3-mediated collagen
glycosylation19 (Supplementary Table 2). The neighboring region
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comprising residues 187–191 is characterized by a non-conserved
poly-Asp repeat (Supplementary Fig. 10B), and mutations on
Asp190 and Asp191 were reported to abolish the glycosyltrans-
ferase activity19 (Supplementary Table 2). In UDP-bound
structures, this short loop forms contacts with the stabilized
Gly72-Gly87 loop directly involved in UDP interaction (Fig. 2b).
Although Asp190 and Asp191 are not directly involved in
binding of enzyme cofactors and substrates, both residues point
towards the active site near Trp145, possibly playing roles as
nucleophiles during the glycosyltransferase reaction, or support-
ing solvent-bridged interactions with the glycan co-substrates.
Interestingly, the pathogenic LH3 mutation N223S, responsible
for an LH3-dependent developmental connective tissue disorder
with phenotype resembling osteogenesis imperfecta11 localizes in
close proximity to the identiﬁed LH3 GT/GGT catalytic site
(Fig. 2a). This mutation was reported to introduce a new N-
linked glycosylation site on residue Asn221, resulting in strongly
reduced LH3 GT/GGT activity (Supplementary Table 2). We
produced this enzyme variant obtaining a folded, dimeric enzyme
comparable with wild type LH3 (Supplementary Fig. 11A, B).
However, due to pronounced instability and high propensity to
degradation for this mutant, we could not unambiguously
conﬁrm that this disease-linked mutant bears an additional
glycosylation (Supplementary Fig. 11A). LH3 N223S showed
severely reduced lysyl hydroxylase and fully abolished glycosyl-
transferase activities (Fig. 2c, Supplementary Fig. 11C). As we did
not observe changes in LH3 oligomeric assembly in the presence
of this pathogenic mutation (Supplementary Fig. 11B), we
concluded that the lack of enzymatic activity caused by this
variant is likely due to the alterations in enzyme stability, possibly
introduced by the novel glycosylation on Asn221, which would
interfere with recognition of acceptor substrate molecules.
The C-terminal part of the ﬁrst glycosyltransferase domain of
LH3 incorporates other uniquely structured regions: a long, non-
conserved beta hairpin constituted by residues Val229-Ala244
points towards the domain face opposite to the GT/GGT catalytic
site. This segment is stabilized by numerous hydrophobic
contacts including Phe233, Trp273 and with a non-conserved
α-helix formed by residues Pro257-Glu276, which is sandwiched
between the ﬁrst and the second domain of LH3 (Fig. 2d).
Residues linking these two domains extend to a solvent-exposed
region of the enzyme comprising the Cys279-Cys282 disulﬁde
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Fig. 2 Insights into LH3 glycosyltransferase activity. a Co-crystallizations with Mn2+ and donor substrates revealed clear electron density (2Fo-Fc omit
electron density maps, green mesh, contour level 1.2 σ) for the metal ion and for UDP in the catalytic site of the N-terminal GT domain. Residues involved in
coordination of the metal ion are shown with orange sticks, while residues interacting and stabilizing UDP binding are shown in blue. Residue Asn223,
found mutated into a Ser and causing pathogenic phenotypes similar to osteogenesis imperfecta, is shown with magenta sticks. b Binding of donor
substrates induces conformational changes in the GT domain. Shown is a superposition of ligand-free (yellow), Mn2+-bound (blue), and Mn2+-donor
substrate-bound (violet) structures of LH3 GT domain. Only the UDP-Gal-bound structure is shown; the conformation observed in UDP-Glc-bound
structure is identical. Flexible loop 72–87 becomes well deﬁned only in donor substrate-bound structures; in these structures, residues Trp145 and Trp148
adopt different conformations. c Luminescence-based assays for the evaluation of LH3 GT enzymatic activity show that mutants W75A, Y114A, and N223S
are inactive. Control experiments were performed without adding enzyme. Error bars represent standard deviations from average of triplicate independent
experiments. Statistical evaluations based on pair sample comparisons between uncoupled and coupled assay values using Student’s t-test. *P-value <0.05;
***P-value <0.001. d Details of the interface between the N-terminal (GT, blue) and the central (AC, orange) LH3 glycosyltransferase domain. Residues
found at the interface are shown as sticks (side chain view only). The disulﬁde bond found in the linker region between the two domains is shown with
yellow spheres on the sulfur atoms
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bridge and a ﬂexible loop extending from Asp285 to Gly292, and
not visible in the electron density. Antibodies targeting these
residues were reported to reduce GT activity17, suggesting a role
for this surface-exposed region in modulating accessibility of
acceptor substrates to the identiﬁed glycosyltransferase catalytic
site (Supplementary Table 2).
In the central LH3 domain, two previously suggested candidate
metal ion binding sites are present, identiﬁed by a DxD (Asp392,
Ala393, Asp394) and a DxDxD (Asp486, Thr487, Asp488,
Pro489, Asp490) motif, respectively18,19 (Supplementary Fig.
12). Co-crystallization experiments with metal ions and glycosyl-
transferase substrates and products did not highlight any
appreciable differences within this domain compared to ligand-
free structures (Supplementary Fig 13A). On the contrary,
superposition of the two glycosyltransferase domains of
LH3 showed remarkable differences, emphasized by the unique
features found in the ﬁrst domain (Supplementary Fig. 8,
Supplementary Fig. 13B). Although the overall fold of the second
domain shares higher similarity than the ﬁrst with known GT-A
type glycosyltransferases (Supplementary Fig. 13C, D), extensive
mutagenesis experiments did not allow clear identiﬁcation of
residues implicated in metal ion or substrate binding for LH3 GT
catalytic activity18,19 (Supplementary Table 2). Our structures
highlight an unusual conformation for the Val304-Phe310 loop:
this region overlaps with the donor substrate binding site
observed in structural homologs, strongly interfering with donor
substrate binding (Supplementary Fig. 13E). Furthermore,
recombinant N-terminal LH3 constructs devoid of this domain
were still capable of glycosylating collagen peptides similar to the
wild-type enzyme19 (Supplementary Table 2). Collectively, these
data indicate that despite the overall conservation of the
glycosyltransferase fold, this domain may have lost its enzymatic
capabilities during evolution. It may therefore constitute a non-
catalytic accessory element within the LH3 architecture, possibly
involved in collagen substrate recognition or interactions with LH
binding partners. Thus, we named the LH3 N-terminal domain
catalytic glycosyltransferase (GT), and the central domain
accessory (AC).
Structural insights into LH3 lysyl hydroxylase activity. The C-
terminal domain of LH3 hosts the lysyl hydroxylase catalytic site
of the enzyme. This domain shows the typical DSBH fold,
characterized by two β-sheets with antiparallel β-strands ﬂanked
by three α-helices (Fig. 3a). This fold is preceded by two addi-
tional short helices covering residues Thr523 to Asp554, serving
as a buffer platform between the AC and the LH domain (Fig. 1a).
Residues 590–610 constitute a ﬂexible loop capping the LH cat-
alytic site. Superposition with identiﬁed structural homologs
highlighted the high conservation of the overall fold and the
consistent presence of highly ﬂexible residues near the Fe2+, 2-
OG binding site (Supplementary Fig. 14A). The recently deter-
mined structure of a viral L230-LH domain39 shows very high
overall similarity (r.m.s.d.= 1.3 Å), with the exception of surface-
exposed residues Ser550-Ile558, likely due to the non-conserved
N-linked glycosylation at residue Asn548 (Supplementary
Fig. 14B); also the structure of the viral LH fragment shows a
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Fig. 3 Insights into LH3 lysyl hydroxylase activity. a All our LH3 structures consistently show clear electron density for bound Fe2+ and 2-OG in the LH
catalytic cavity (2Fo-Fc omit electron density maps, green mesh, contour level 1.2 σ). Residues involved in interactions with Fe2+ and 2-OG are shown with
green sticks. b Co-crystallizations with Fe2+ allow identiﬁcation of a second metal ion bound near the LH catalytic site that stabilizes the ﬂexible capping
loop 590–610 (shown in pink). c Evaluation of collagen substrate coupled and uncoupled LH3 LH activities as a function of Fe2+ concentration. Error bars
represent standard deviations from average of triplicate independent experiments. d In Fe2+ co-crystal structures, the conformation observed for residue
Arg599 mimics the collagen lysine substrate in front of the 2-OG cofactor, yielding a non-productive ternary complex. Shown is the superposition of this
conformation found in the LH3 LH domain (green) with an homologous algal prolyl-4-hydroxylase (white) in complex with a short poly-PS peptide (yellow)
43. The LH3 loop 590–610 is shown in pink
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completely ﬂexible capping loop. All our LH3 structures sys-
tematically showed Fe2+ and 2-OG in the electron density near
the core of this domain (Fig. 3a), conﬁrming that these cofactors
are tightly bound to the enzyme and providing a possible
explanation for the observed substrate uncoupled LH enzymatic
activity (Supplementary Fig. 1C, D). Given the high structural
similarity of our LH3 structure with the LH domain of the viral
variant, we were surprised not to ﬁnd the 2-OG cofactor in this
structure. We interpreted this difference as due to usage of a
prokaryotic expression system for the recombinant production of
the viral homolog39. In human LH3, the Fe2+ ion is stabilized by
interactions with residue His719 and with residues His667 and
Asp669, which constitute part of a HxD motif fully conserved in
the Fe2+, 2-OG dioxygenase enzyme family (Supplementary
Fig. 15). Mutations in these residues17, including a recently
identiﬁed pathogenic variant of LH2 causing Bruck syndrome8,
were found to completely abolish LH activity (Supplementary
Table 2). Pathogenic LH3 mutations causing premature C-
terminal enzyme truncations lacking His719 were found incap-
able of hydroxylating collagen lysines, although retaining GT/
GGT activities11 (Supplementary Table 2). Residues Tyr656,
Cys691 and Arg729 are fully conserved among LH isoforms and
delimit the pocket hosting the 2-OG cofactor (Supplementary
Fig. 14C). In particular, the side chain of free Cys691 contributes
to the positioning of the carboxyl moiety of the 2-OG cofactor in
the direction of Arg729, forming a salt bridge with the guanidi-
nium group of this residue. In addition, biochemical mutations of
Arg729 in homologous LH1 (Arg719 in LH3) were reported to
cause complete loss of LH activity due to decreased binding
afﬁnity for 2-OG42; these data are also in agreement with a recent
report analyzing these mutations in the viral L230-LH homolog39
(Supplementary Table 2).
Excess Fe2+ induces a state showing substrate mimicry. By
increasing the Fe2+ concentration in crystallization experiments,
we serendipitously found that this metal ion contributes to the
overall enzyme stabilization, systematically enhancing the quality
and the resolution of X-ray diffraction data. Analysis of electron
density maps allowed the identiﬁcation of a second Fe2+ in the
LH domain, coordinated by residues His595, Asp597, Asp611 and
His613 (Fig. 3b). Metal ion coordination stabilizes the ﬂexible
capping loop 590–610 into a conformation that completely plugs
the LH catalytic site, in proximity to the dimer interface (Sup-
plementary Fig. 16A). We could observe a very similar arrange-
ment, although slightly more ﬂexible, by replacing Fe2+ with Mn2
+ in crystallization experiments (Supplementary Fig. 16B). Early
reports indicated that LH enzymes may be inhibited by high
concentrations of metal ions20. We probed LH3 enzymatic
activity in the presence of increasing concentrations of Fe2+, and
found that the enzymatic activity peaks at 25 μM Fe2+ con-
centration. Higher metal ion concentrations yield signiﬁcant
reduction of LH uncoupling, but do not seem to affect the
enzymatic reactivity in the presence of synthetic peptide sub-
strates (Fig. 3c). In the metal-ion stabilized conformations we also
found that residue Arg599 forms a salt bridge with the 2-OG co-
substrate, yielding a conformation that may mimic the collagen
lysine substrate. The positioning of Arg599 indeed superimposes
to that of a collagen proline residue as observed in a homologous
prolyl hydroxylase structure in complex with a short peptide43
(Fig. 3d).
Discussion
Despite being known for over 40 years44, several molecular
aspects underlying collagen lysyl hydroxylases function are still
obscure. Our crystal structures of full-length human LH3
rationalize the accumulated biochemical knowledge, offering a
template to better understand the molecular mechanisms of LH3-
dependent collagen hydroxylation and glycosylation.
The two different enzymatic activities are segregated in two
distinct catalytic sites 80 Å apart within the same enzyme mole-
cule. The overall dimeric arrangement, experimentally validated
through site-directed mutagenesis, shows an elongated tail-to-tail
quaternary assembly (Fig. 1c), characterized by a relatively small
hydrophobic contact platform surrounded by electrostatic con-
tacts that stabilize the dimer interface near the LH catalytic site
(Fig. 1c–e) and closely resemble those recently reported for
homologous human LH2 and viral L23039 (Supplementary
Fig. 14B). As previously suggested, dimerization is essential for
LH activity, whereas disruption of physiological dimers does not
signiﬁcantly perturb the N-terminal glycosyltransferase activities
of LH338,39.
We identiﬁed two glycosyltransferase domains at the N-
terminus of the enzyme characterized by Rossmann fold-like
domain architecture and partial similarity with known GT-A
glycosyltransferases. However, only the ﬁrst domain is active: the
GT domain (residues 33–277) is the solely responsible for gly-
cosyltransferase activities (both GT and GGT), albeit showing
unique features in multiple regions of its fold strongly divergent
from known glycosyltransferases (Supplementary Fig. 8).
Sequence alignments comparing human LH isoforms (Supple-
mentary Fig. 9) and analysis of donor substrate-free and bound
structures do not provide a direct explanation for the lack of GT/
GGT activities in homologous LH1 and LH2. Nearly all residues
surrounding the UDP moiety and shaping the LH3 glycosyl-
transferase catalytic site are conserved, including those involved
in the unprecedented mode of UDP-substrate stabilization
characterized by dual π-π stacking with Trp75 and Tyr114.
Nevertheless, sequence conservation at the rim of the catalytic site
is much lower (Supplementary Fig. 9), suggesting that lack of
collagen substrate recognition may be the reason for the absence
of glycosyltransferase activity in homologous LH isoforms.
The adjacent AC domain does not appear to be directly
involved in enzyme function. Surprisingly, this domain shares the
highest structural similarities with known glycosyltransferases,
and yet it may have lost its function during evolution through
mutations that introduced steric hindrance in the donor and
acceptor substrate binding regions (Supplementary Fig. 13E).
Despite the lack of direct evidence of substrate recognition cap-
abilities, the elongated quaternary structure of the LH3 enzyme
allows to speculate about possible long-range collagen substrate
recognition mechanisms involving this domain. Alternatively, it
may serve as a docking module for interactions with binding
partners, such as the proposed collagen glycosyltransferases
GLT25D1/226 or chaperones like FKBP6524,25.
In the C-terminal LH domain both Fe2+ and 2-OG are natively
retained and consistently found in the electron densities of all our
structures (Fig. 3a). Enzymatic assays show that LH activity is
present without the need for Fe2+ supplementation, demon-
strating that the metal ion remains tightly bound into the active
site during catalysis, and supporting recent reports also indicating
essential roles for the metal ion in folding maintenance of LH
domain39. Concentrations higher than 25 μM affect the LH3
uncoupled catalytic activity, but do not seem to affect substrate
processing. Crystals grown with excess Fe2+ or Mn2+ show sta-
bilization of a substrate gating loop, with formation of a self-
inactivated ternary complex between Fe2+, 2-OG and the side
chain of Arg599 mimicking the collagen lysine substrate and
obstructing the enzyme’s active site (Fig. 3b, c). Despite gating
loops have been described for prolyl-hydroxylases43,45,46, the
presence of a metal ion-induced gating seems a prerogative of LH
enzymes. Given the full conservation in the LH enzyme family of
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amino acid residues involved in coordination of the second Fe2+
(Supplementary Fig. 15), we postulate that a general mechanism
for metal ion-dependent regulation of LH activity may rely on
generation of a self-inactivated resting state with interlocking of
the 591–610 gating loop in front of the catalytic site. Remarkably,
mutation of LH2 conserved homologous Arg599 into a histidine,
as well as other mutations localized on this gating loop, perturb
the enzymatic activity and cause Bruck syndrome7 (Supplemen-
tary Table 2). This corroborates the proposed role of the 590–610
gating loop in modulating substrate accessibility to the LH active
site, and in particular the role of conserved Arg599 as non-
productive substrate mimicry.
The LH3 structures allow understanding the molecular phe-
notypes associated to most of the pathogenic mutations involving
LH enzymes (Fig. 4). The LH3 N223S variant causing connective
tissue disorders similar to osteogenesis imperfecta was reported to
introduce a novel N-linked glycosylation near the cavity hosting
the glycosyltransferase donor substrates. Our experiments show
that this alteration strongly affects the enzyme’s stability, causing
degradation, and completely abolishes GT and GGT activities.
Pathogenic mutations of LH1 responsible for the kyphoscoliotic
variant of the Ehlers-Danlos syndrome were reported to reduce,
but not abolish, mechanisms of collagen recognition and catalysis
(Supplementary Table 2). This is fully consistent with their
localization on the enzyme’s surface, distant from the identiﬁed
catalytic sites, with the exception of pathogenic mutation H706R,
which maps to a conserved residue in close proximity to the
homodimer interface. Conversely, LH2 mutations causing severe
Bruck syndrome are located within the LH active site, either
proximate to the 2-OG binding site, directly involved in Fe2+
coordination, or in the self-inactivated capping loop, also
including the lysine mimicry residue Arg599 (Supplementary
Table 2). Given the recent reports describing implications of
human LH2 and its upregulated enzymatic activity in metastatic
spreading of numerous solid tumors13, our full-length structures
of self-inhibited human LH3 constitute a valid template for
structure-based drug discovery campaigns aiming at blocking
unwanted collagen lysine hydroxylation in tumor
microenvironments.
In conclusion, the crystal structures of full-length human LH3
in complex with various cofactors and donor substrates provide a
molecular understanding of the biochemical knowledge under-
lying the multiple functions of this enzyme. Our data shed light
on the unique molecular architecture of the LH3 glycosyl-
transferase domains, and allow understanding of the molecular
bases of multiple genetic diseases involving LH3 and homologous
human lysyl hydroxylases.
Methods
Chemicals. All chemicals were purchased from Sigma-Aldrich unless otherwise
speciﬁed.
DNA constructs. Human LH3 gene (GenBank accession number BC011674.2) was
obtained from Source Bioscience. Oligonucleotides containing in-frame 5′-BamHI
and 3′-NotI were designed and used to sub-clone the LH3 sequence devoid of the
N-terminal signal peptide into the pUPE.106.08 expression vector, kindly provided
by U-protein Express, BV (U-PE, The Netherlands) and into the pPuro-DHFR,
containing the Streptomyces alboniger puromycin resistance gene (isolated from the
pPUR plasmid, Clontech) and the mouse dihydrofolate reductase cDNA47. Both
expression vectors bear N-terminal signal peptide followed by a N-terminal 6xHis-
tag and a recognition site for Tobacco Etch Virus (TEV) protease prior to an in-
frame BamHI restriction site, as well as an in-frame stop codon after the NotI
restriction site. LH3 mutants were generated using the Phusion Site Directed
Mutagenesis Kit (ThermoFisher Scientiﬁc) following manufacturer’s instructions.
The entire plasmid was ampliﬁed using phosphorylated primers. For all mutants
the forward primer introduced the mutation of interest (Supplementary table 4).
All expression plasmids were checked by Sanger sequencing prior to usage.
Recombinant LH3 expression from stable HeLa cell lines. The pPuro-DHFR-
LH3 construct was transfected into human cervical carcinoma cells (HeLa S3,
provided by ATCC and further selected for high transfection efﬁciency by
Dr.F. Peverali, Consiglio Nazionale delle Ricerche, Pavia) using the Lipofectamine
LTX reagent (Invitrogen). Cells were not authenticated and not tested for myco-
plasma contamination. Stably transfected clones, isolated with 1 mgmL−1 pur-
omycin (Invivogen), were subjected to step-wise selection with increasing
methotrexate concentrations to select for cells containing multiple copies of the
plasmid. Cells were routinely cultured at 37 °C in 5% CO2 in high-glucose DMEM
supplemented with 10% foetal calf serum (Biowest), 1× non-essential amino acids,
2 mM L-glutamine and 1× penicillin-streptomycin. Clones expressing high yields
of PLOD3 were identiﬁed by SDS-PAGE analysis after imidazole elution from
small-scale immobilized metal ion afﬁnity puriﬁcation using Nickel sepharose
beads (GE Healthcare).
Recombinant LH3 expression from transient HEK293 cells. Recombinant tag-
ged LH3 mutants were produced using suspension cultures of HEK293F (Invi-
trogen) cells. Cells were not authenticated and not tested for mycoplasma
contamination. Cells were transfected at cell densities of 1 million mL−1 using 3 μg
of polyethyleneimine (PEI; Polysciences, Germany) for 1 μg of pUPE.106.08-LH3
plasmid DNA per mL of cells. Cultures were supplemented with 0.6% Primatone
RL 4 h after transfection. The cell medium containing secreted LH3 was collected
6 days after transfection by centrifugation at 1000 × g for 15 min.
Puriﬁcation of LH3 enzymes. The LH3-containing medium from either HeLa or
HEK293 cell cultures was ﬁltered through a syringe 0.2 mm ﬁlter. The pH and ionic
strength of the ﬁltrated medium were adjusted using a concentrated buffer stock to
reach a ﬁnal concentration of 25 mM 4-(2-hydroxyethyl)−1-piper-
azineethanesulfonic acid (HEPES)/NaOH, 500 mM NaCl, 30 mM imidazole, pH
GT/GGT
active site
LH active
site
LH capping
loop
N223S
C691A*
Fig. 4 Mapping of disease-related mutations identiﬁed in LH enzymes on the LH3 crystal structure. The positions of pathogenic mutations causing Ehlers-
Danlos type VI syndrome in LH1 (cyan), Bruck syndrome type II in LH2 (yellow), and connective tissue diseases sharing phenotype features with
osteogenesis imperfecta (red) in LH3 are shown as spheres on the LH3 dimer structure. Mutations N223S and C691A*, found on LH3, are labeled in red in
one of the two monomers. A complete list of mutations reported in the literature and their signiﬁcance based on evaluation of their mapping on the LH3
crystal structure is shown in Supplementary Table 2
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8.0. LH3 was puriﬁed using afﬁnity and size-exclusion chromatography on Äkta
systems (GE Healthcare). The ﬁltered supernatant was ﬁrst loaded onto a 20 mL
His-Prep FF column (GE Healthcare) and eluted using 250 mM imidazole. The
eluate was then loaded onto a 5 mL HiTrap desalting FF column (GE Healthcare)
equilibrated in 25 mM HEPES, NaOH, 500 mM NaCl, pH 8.0. The N-terminal
histidine-tag was cleaved using overnight TEV protease digestion at 4 °C followed
by afﬁnity-based removal of TEV protease and His-tag using a 5 mL HisTrap FF
(GE Healthcare). The protein was concentrated to 5 mgmL−1 using 30,000
MWCO Vivaspin Turbo centrifugal ﬁlters (Sartorius), then loaded onto a Superdex
200 10/300 GL (preparative scale) or onto a Superdex 200 5/150 GL (analytical
scale) columns (GE Healthcare) equilibrated with 25 mM HEPES/NaOH, 200 mM
NaCl, pH 8.0. LH3-containing fractions as assessed from SDS-PAGE analysis were
pooled, concentrated and stored at −80 °C until further usage.
LH3 deglycosylation. Wild-type LH3 and mutants T672N, L714N, and W148N-
L150T were subject to deglycosylation to validate the introduction of an additional
glycosylation site through mutagenesis. 20 μL protein at 0.15 mgmL−1 were ﬁrst
incubated with 1X Glycoprotein Denaturing Buffer (New England BioLabs) and
denatured at 95 °C for10 min. 1X glycobuffer 2 (New England BioLabs), 1% NP-40,
and 0.2 μL (100 Units) of PNGase F (New England BioLabs) were added to the
reaction mix, which was further incubated for 2 h at 37 °C. PNGase F-treated and
untreated samples were then analyzed using western blotting with rabbit anti-LH3
antibody (Proteintech 11027–1-AP) in a 1:1000 ratio followed by anti-rabbit HRP-
conjugate antibody (Sigma-Aldrich A0545) in a 1:3000 ratio.
ICP-MS measurements. To measure the number of tightly bound divalent metal
ions 3 mg of LH3 were diluted in 5 mL 25 mM HEPES, 500 mM NaCl, pH 8.0.
Three aliquots of 1 ml each were kept overnight with 0.5 mL 65% ultra-pure HNO3
and 0.1 mL 30% w/w H2O2, then diluted to 5 mL with Milli-Q water and analyzed
by ICP-MS. The measurements of Fe and Mn were performed on a Perkin Elmer
Mod ELAN DRC-e instrument, following the standard procedures suggested by the
manufacturer. Quantitative determinations were obtained by the external standard
calibration with ﬁve standards (0, 5, 10, 50, 100, and 300 µg L−1) daily prepared in
the same buffer used for samples preparation, at the same dilution and HNO3
concentration. Only Fe was quantiﬁed in each replicate solution, with standard
deviation of the mean value of 8%, obtaining a molar ratio Fe/LH3= 1, while Mn
was present as impurity in the blank and in the samples.
Crystallization of LH3. LH3 spherulites were found in nanoliter-dispensed dro-
plets (0.1 μL protein at 4 mgmL−1+ 0.1 μL reservoirs) using commercial crystal-
lization screens in sitting vapor diffusion drop plates. These spherulites were
initially optimized by mixing 0.5 μL of protein concentrated at 3.5 mgmL−1 and
0.5 μL of reservoir solution composed of 600 mM sodium formate, 12% poly-
glutamic-acid (PGA-LM, Molecular Dimensions), 100 mM HEPES/NaOH, pH 7.8.
These crystals diffracted to a maximum of 5 Å. Crystal quality was improved
through sequential runs of macro-seeding of LH3 crystals using the same crys-
tallization mixture with slight variations in protein concentration. Co-
crystallization experiments were performed by setting up the same seeding con-
ditions, and supplementing the protein solution with mixtures of 500 μM FeCl2,
500 μM MnCl2, 1 mM UDP-galactose, 1 mM UDP-glucose (Supplementary
Table 1). Crystals were cryo-protected with the mother liquor supplemented with
20% glycerol, harvested using MicroMounts Loops (Mitegen), ﬂash-cooled and
stored in liquid nitrogen prior to data acquisition. Heavy atom derivatives were
prepared by soaking the LH3 crystals in mother liquor conditions containing 1 mM
K2HgBr4. Crystals were incubated with the heavy atom solution for at least 5 h at
4 °C prior to cryo protection, harvesting and ﬂash-cooling in liquid nitrogen.
Diffraction data collection and structure reﬁnement. Diffraction data from LH3
crystals were collected at various beamlines of the European Synchrotron Radiation
Facility, Grenoble, France and at the Swiss Light Source, Villigen, Switzerland
(details in Supplementary Table 1). Single wavelength Anomalous Dispersion
(SAD) experiments at the Hg edge were performed at the ESRF ID30B beamline,
whereas high multiplicity long-wavelength native SAD data (57 data sets of 360°
from 6 different crystals) were collected at the SLS X06DA beamline as described
elsewhere48. The data, which showed strong anisotropy (Supplementary Fig. 3),
were processed with autoPROC49 including STARANISO50. Statistics are sum-
marized in Suppl. table 1. Hg heavy atom sites were identiﬁed using SHELXC/D51
with the HKL2MAP GUI52. Experimental phasing with the Hg SAD data using
SHELXE51 and SHARP53 yielded a partial model. Completion of the model could
only be achieved by combining the latter with high multiplicity native SAD data
using the CRANK2 pipeline54 followed by iterations of automatic and manual
model building using BUCCANEER55 and COOT56. Subsequent LH3 structures
were determined using the initial LH3 structural model in molecular replacement
runs with PHASER57. Final 3D models were generated using iterations of auto-
matic reﬁnement using PHENIX58 alternated with manual adjustments using
COOT56. Validation of structure quality was carried out with Molprobity59, the
RCSB PDB Validation Server60, and PDB-CARE61. Final reﬁnement statistics are
listed in Suppl. Table 1. Structural ﬁgures were generated using PyMol62.
SAXS data collection and analysis. Solution scattering data were collected at
ESRF BM29 using a sec−1 frame rate on Pilatus 1M detector located at a ﬁxed
distance of 2.87 m from the sample, allowing a global q range of 0.03–4.5 nm with a
wavelength of 0.01 nm. SEC-SAXS experiments were carried out using Nexera
High Pressure Liquid/Chromatography (HPLC; Shimadzu) system connected
online to SAXS sample capillary63. For these experiments, 50 μL of LH3 con-
centrated at 4 mgmL−1 were injected into a Superdex 200 PC 3.2/300 Increase
column (GE Healthcare), pre-equilibrated with 25 mM HEPES/NaOH, 200 mM
NaCl, pH 8.0. For ofﬂine batch sample analysis, 50 μL of LH3 at concentrations
ranging from 0.5 to 9 mgmL−1 were injected using the dedicated automatic sample
changer available at the BM29 beamline64. For SEC-SAXS data, frames corre-
sponding to LH3 protein peak were identiﬁed, blank subtracted and averaged using
CHROMIXS65, whereas batch concentration series were analyzed using PRIMUS66.
Radii of gyration (Rg), molar mass estimates and distance distribution functions P
(r) were computed using the ATSAS package67 in PRIMUS66. Comparison of
experimental SAXS data and 3D models from crystal structures was performed
using CRYSOL68. A summary of SAXS data collection and analysis results is shown
in Suppl. Table 3.
Determination of LH activity using mass spectrometry. Synthetic collagen
peptides were purchased from China peptides. Peptides tested were ARGIK-
GIRGFS, GIKGIKGIKGIK, and IKGIKGIKG sequences. LH3 5 μM was incubated
with 500 μM FeCl2, 1 mM 2-OG, 2 mM ascorbate and 1 mM peptide substrate.
Reactions were allowed to proceed for 1 h at 37 °C. In total 20 μL of each sample
were previously acidiﬁed by addition of 1 μL of formic acid (FA) and then analyzed
on an LC–MS system (Thermo Finnigan, USA) consisting of a thermostated col-
umn oven Surveyor autosampler controlled at 25 °C; a quaternary gradient Sur-
veyor MS pump equipped with an UV/vis detector and an Ion Trap (LCQ
Advantage Max) mass spectrometer with electrospray ionization ion source con-
trolled by Xcalibur software 2.0.7. Peptides were separated by RP-HPLC on a
Jupiter (Phenomenex, USA) C18 column (150 × 2mm, 4 μm, 90 Å particle size)
using a linear gradient (2–60% solvent B in 60 min) in which solvent A consisted of
0.1% aqueous FA and solvent B of acetonitrile (CAN) containing 0.1% FA. Flow-
rate was 0.2 mL/min. Mass spectra were generated in positive ion mode under
constant instrumental conditions: source voltage 5.0 kV, capillary voltage 46 V,
sheath gas ﬂow 20 (arbitrary units), auxiliary gas ﬂow 10 (arbitrary units), sweep
gas ﬂow 1 (arbitrary units), capillary temperature 200 °C, tube lens voltage −105 V.
Spectra analyses were performed using Xcalibur software 2.0.7.
Biochemical evaluation of LH activity. Reaction mixtures (5 μL total volume)
containing wild-type or mutant LH3 samples at 0.2 mg mL−1 were prepared by
sequentially adding 0–1 mM peptide substrate or 4 mgmL−1 gelatin in water,
(solubilized through heating denaturation at 95 °C for 10 min), 500 μM ascorbate,
100 μM 2-OG, and variable concentrations of FeCl2 (0–200 μM), and let incubate
for 1 h at 37 °C. Reactions were stopped by heating samples at 95 °C for 2 min prior
to transfer into Proxiplate white 384-well plates (Perkin-Elmer), then 5 μL of the
Succinate-Glo reagent I (Promega) were added and let incubate 1 h at 25 °C, after
that 10 μL of the Succinate-Glo reagent II (Promega) were added and let incubate
10 min at 25 °C. The plates were then transferred into a GloMax plate reader
(Promega) conﬁgured according to manufacturer’s instructions for luminescence
detection. All experiments were performed in triplicates. Control experiments were
performed using identical conditions by selectively removing LH3, 2-OG or pep-
tide substrates. Data were analyzed and plotted using the GraphPad Prism
7 software69.
Biochemical evaluation of GT and GGT enzymatic activities. Reaction mixtures
(5 μL total volume) containing wild-type or mutant LH3 samples at 0.2 mg mL−1
were prepared by sequentially adding 0–1 mM peptide substrate, 500 μM ascorbate,
100 μM 2-OG, 50 μM FeCl2, and let incubate for 1 h at 37 °C. Reactions mixtures
were then supplemented with 50 μMMnCl2, and 50μM UDP-Gal or UDP-Glc, and
let incubate for 1 h at 37 °C. Experiments using gelatin as substrate were performed
by sequentially adding 4 mgmL−1 gelatin in water, (solubilized through heating
denaturation at 95 °C for 10 min), 50 μM MnCl2, and 100 μM UDP-Gal or UDP-
Glc to the LH3 samples at 0.2 mg mL−1, and let incubate for 1 h at 37 °C. All
reactions were stopped by heating at 95 °C for 2 min, prior to transfer into Prox-
iplate white 384-well plates (Perkin-Elmer), then 5 μL of the UDP-Glo lumines-
cence detection reagent (Promega) were added and let incubate 1 h at 25 °C.
Detection was carried out as described for the LH enzymatic activity. All experi-
ments were performed in triplicates. Control experiments were performed using
identical conditions by selectively removing LH3, donor or acceptor substrates.
Data were analyzed and plotted using the GraphPad Prism 7 software69.
Surface-plasmon resonance. Wild-type and mutant LH3 preparations were
immobilized onto a carboxymethylated dextran (CM5) sensor chip (GE Health-
care) using a mixed solution of 200 mM 1-ethyl-3-(3-dimethylaminopropyl)car-
bodiimide hydrochloride (EDC) in 50 mM N-hydroxysuccinimide (NHS) in a
Biacore T200 SPR instrument (GE Healthcare). Excess reactive groups were
blocked with 1M ethanolamine. Efﬁcient immobilization of LH3 samples was
judged based on the SPR signal collected. For each of the tested samples, 3000 RU
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were reached. A control ﬂow cell 1 was pre-activated and blocked using the same
protocol as above but without protein samples, and used as reference cell during
measurements. Collagen peptides were dissolved in running buffer (PBS-P 0.01%)
and injected as two-fold dilution concentration series of eight points each using a
ﬂow of 5 μl min−1. Two replicates of each concentration were injected. Data
analysis was performed using the Biacore T200 evaluation software (GE Health-
care) using a 1:1 steady-state afﬁnity model.
Data availability. Coordinates and structure factors have been deposited in the
Protein Data Bank (PDB) with accession codes 6FXK, 6FXM, 6FXR, 6FXT, 6FXX,
6FXY. SEC-SAXS experimental data and ab-initio model have been deposited in
Small Angle Scattering Biological Data Bank (SASBDB) with accession code
SASDDW4. Other data are available from the corresponding author upon rea-
sonable request.
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